Entdoc, exactly.
The exosome cancer test success is a VALIDATION of phosphatidylserine and its blockade by Bavi.
Your term of "Bavi spin-off" is superb. Posters on the board may have thought that exosomes were something "out of the blue" from PPHM, but in fact, it's part and parcel of how Bavi works.
It's Wolchok. It's Brekken. It's Birge. It's Gabrilovitch. They all know that exposed PS is a terrible signal in the tumor microenvironment and it must be blocked off.
PS-covered vesicles are detected as exosomes.
The surprise that our investment is really going to take off because of a test kit is not really a surprise.
It was Bavi, or a "Bavi spin-off, as you say, all along.
Regards,
Joe Six Pack
Market Data 
Markets 
AI
